Skip to main content
    C

    Celldex Therapeutics Inc (CLDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $28.04
    -0.55 (-1.92%)

    Market Cap: $2.25B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Celldex Therapeutics Inc (CLDX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Celldex Therapeutics (CLDX) has a market cap of $2.25B and an enterprise value of $2.22B. It kept -196854.78% of revenue as net income over the last 12 months. Revenue fell 93.96% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 1.20% below the market cap, as cash exceeds debt.

    Market Cap$2.25B
    Enterprise Value$2.22B
    Latest price (Nov 17, 2026)$28.04

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.89% in the quarter ended Sep 30, 2026 and grew 8.84% a year over 2 years.

    Shares Outstanding78.53M
    Shares Change (YoY)+18.23%
    Shares Change (QoQ)+0.89%
    Share Count Growth (2Y CAGR)+8.84%

    Valuation Ratios

    P/B Ratio3.4x
    P/TBV Ratio3.5x

    Price Statistics

    The stock is up 9.75% over 52 weeks and trades 11.10% below its 50-day average.

    Beta (1Y)1.22
    52-Week Change+9.75%
    1-Month Change-5.49%
    3-Month Change-32.76%
    6-Month Change-7.00%
    5-Year Change-29.24%
    10-Year Change-36.26%
    Total Return (1Y)+9.75%
    Total Return (3Y CAGR)-1.22%
    Total Return (5Y CAGR)-7.99%
    Return vs SPY (1Y)-1.94%
    Max Drawdown (1Y)-38.65%
    Max Drawdown (3Y)-70.84%
    Sharpe Ratio (1Y)0.18
    Correlation with SPY (1Y)0.33
    50-Day Average$31.54
    200-Day Average$32.88
    52-Week Range$22.33 to $45.14
    RSI (14 Days)40.3
    Average Volume (20 Days)872.67K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 10.97x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio10.97x
    Quick Ratio10.97x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -47.59% over the last 12 months, against a 5-year average of -30.88%.

    Return on Equity (ROE)-47.59%
    Return on Assets (ROA)-42.83%
    ROE (5Y Average)-30.88%
    ROA (5Y Average)-28.48%
    ROIC (5Y Average)-43.06%
    Asset Turnover0.00x
    Receivables Turnover0.54x

    Scores

    CLDX has an Altman Z-Score of 13.85, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score13.85
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $157.00K over the last 12 months.

    Revenue$157.00K
    Revenue Growth (YoY)-93.96%
    Gross Profit$157.00K
    Operating Income-$334.46M
    Pretax Income-$309.06M
    Net Income-$309.06M
    Reported EPS (TTM)-$4.30

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 90.01% of the $721.53M in total assets.

    Cash and Equivalents$26.95M
    Total Debt$0
    Net Cash$26.95M
    Net Cash Per Share$0.34
    Working Capital$603.22M
    Shareholder Equity$649.47M
    Book Value Per Share$8.27
    Tangible Book Value$622.28M
    Tangible Book Per Share$7.92
    Total Assets$721.53M
    Total Liabilities$72.06M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $7.77M of capital spending, operating cash flow left -$259.74M of free cash flow.

    Operating Cash Flow-$251.97M
    Capital Expenditures$7.77M
    Free Cash Flow-$259.74M
    FCF Per Share-$3.31
    Depreciation and Amortization$7.73M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -213033.76%.

    Gross Margin100.00%
    Operating Margin-213033.76%
    Pretax Margin-196854.78%
    Net Margin-196854.78%
    FCF Margin-165438.85%

    Growth

    Revenue fell 13.13% a year over 3 years.

    Revenue Growth (3Y CAGR)-13.13%
    Revenue Growth (5Y CAGR)-26.93%
    Book Value Per Share Growth (2Y CAGR)-1.97%
    Tangible Book Per Share Growth (2Y CAGR)-1.35%

    Revenue and profit by year

    Dividends and Yields

    CLDX does not pay a dividend. Its free cash flow yield is -11.80%.

    FCF Yield-11.80%
    Buyback Yield-14.87%
    Shareholder Yield-14.87%

    Stock Splits

    The last split was a 1-for-15 reverse split on Feb 11, 2019.

    Last Split DateFeb 11, 2019
    Split TypeReverse split
    Split Ratio1:15

    Analyst Forecast

    Consensus estimates put revenue growth at 114.50% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+114.50%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About CLDX

    What is CLDX's market cap?

    Celldex Therapeutics has a market cap of $2.25B. Its enterprise value, which adds debt and subtracts cash, is $2.22B.

    How many shares of CLDX are outstanding?

    Celldex Therapeutics has 78.53M shares outstanding. The count is up 18.23% from a year earlier.

    Does CLDX pay a dividend?

    No. Celldex Therapeutics does not pay a dividend.

    How much debt does CLDX have?

    Celldex Therapeutics has $0 of total debt and $26.95M of cash and equivalents, a net cash position of $26.95M.